Metazosin

Drug Profile

Metazosin

Alternative Names: Kenosin; VUFB 15111

Latest Information Update: 20 Jul 2007

Price : $50

At a glance

  • Originator VUFB
  • Class Antihypertensives; Piperazines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute heart failure
  • Discontinued Benign prostatic hyperplasia; Glaucoma; Hypertension

Most Recent Events

  • 15 Sep 2003 Leciva has merged with Slovakofarma to form Zentiva
  • 13 Feb 2001 Metazosin is available for licensing
  • 08 Sep 1999 A study has been added to the Men's Health therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top